Literature DB >> 32783906

Blood NAD levels are reduced in very old patients hospitalized for heart failure.

Marie Breton1, Jean-François Costemale-Lacoste2, Zhenlin Li3, Carmelo Lafuente-Lafuente4, Joël Belmin4, Mathias Mericskay5.   

Abstract

BACKGROUND: Age-associated decline in nicotinamide adenine dinucleotide (NAD) tissue levels has emerged as potential driving mechanism in the establishment of energy metabolism perturbations in the context of chronic diseases, notably heart failure.
OBJECTIVE: The aim of this study was to measure the blood NAD levels in a healthy blood donor population and in a population of elderly patients hospitalized for decompensated heart failure.
METHOD: Whole blood sample was collected from 151 healthy voluntary blood donors, aged 19 to 68 years, and from 19 patients aged 75 to 101 years and hospitalized for decompensated heart failure in a geriatric ward. Metabolites were extracted by the hot buffered ethanol procedure and NAD was quantified in triplicate for each sample.
RESULTS: The mean concentration of NAD in blood of healthy donors was 23.4 (SD 4.05) μmol/L. There was no significant correlation between NAD levels and donors' age nor sex in the healthy population when studied as a whole. However, the linear regression curves of NAD concentration plotted against age differed between males and females (p = 0.0283) with a trend in males to decline with age that was not observed in females. The mean concentration of NAD in whole blood samples of the geriatric population was 20.7 (SD 3.6) μmol/L (p = 0.007 versus the healthy blood donor population). There were no differences between males and females (p = 0.7) nor between patients with ejection fraction inferior or superior to 50% (p = 0.86) in the geriatric population.
CONCLUSION: This study highlighted a diminution of NAD blood levels for elderly patients hospitalized for decompensated heart failure in comparison to a healthy population, suggesting that new therapeutics to restore NAD stock and energy metabolism would be a major progress in the management of this type of geriatric patients.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Biomarker; NAD+; Nicotinamide; Whole blood

Mesh:

Substances:

Year:  2020        PMID: 32783906     DOI: 10.1016/j.exger.2020.111051

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  3 in total

1.  Efficient Assay and Marker Significance of NAD+ in Human Blood.

Authors:  Natalia V Balashova; Lev G Zavileyskiy; Artem V Artiukhov; Leonid A Shaposhnikov; Olga P Sidorova; Vladimir I Tishkov; Angela Tramonti; Anastasia A Pometun; Victoria I Bunik
Journal:  Front Med (Lausanne)       Date:  2022-05-19

2.  Association of Human Whole Blood NAD+ Contents With Aging.

Authors:  Fan Yang; Xuan Deng; Ye Yu; Lei Luo; Xianda Chen; Jinping Zheng; Yugang Qiu; Feng Xiao; Xiaomei Xie; Yuzheng Zhao; Jun Guo; Feifei Hu; Xuguang Zhang; Zhenyu Ju; Yong Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-21       Impact factor: 5.555

Review 3.  Targeting NAD+: is it a common strategy to delay heart aging?

Authors:  Bing Liang; Xin-Lin Liu; Yang Yuan; Wen-Jing Liu; Bing-Huan Huang; Shan-Bo Yang; Yuan-Zhen Gao; Jing-Sen Meng; Meng-Jiao Li; Ting Ye; Chuan-Zhi Wang; Xiao-Kun Hu; Dong-Ming Xing
Journal:  Cell Death Discov       Date:  2022-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.